{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T12:24:05Z","timestamp":1781871845378,"version":"3.54.5"},"reference-count":41,"publisher":"National Institute for Health and Care Research","issue":"16","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/non-commercial-government-licence\/non-commercial-government-licence.htm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["14\/49\/159"],"award-info":[{"award-number":["14\/49\/159"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalslibrary.nihr.ac.uk"],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"\n Background<\/jats:title>\n Uncertainty persists about whether or not statins cause symptomatic muscle adverse effects (e.g. pain, stiffness and weakness) in the absence of severe myositis.<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n To establish the effect of statins on all muscle symptoms, and the effect of statins on muscle symptoms that are perceived to be statin related.<\/jats:p>\n <\/jats:sec>\n \n Design<\/jats:title>\n A series of 200 double-blinded N-of-1 trials.<\/jats:p>\n <\/jats:sec>\n \n Setting<\/jats:title>\n Participants were recruited from 50 general practices in England and Wales.<\/jats:p>\n <\/jats:sec>\n \n Participants<\/jats:title>\n Patients who were considering discontinuing statin use and those who had discontinued statin use in the last 3 years because of perceived muscle symptoms.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Participants were randomised to a sequence of six 2-month treatment periods during which they received 20\u2009mg of atorvastatin daily or a matched placebo.<\/jats:p>\n <\/jats:sec>\n \n Main outcome measures<\/jats:title>\n The primary outcome was self-reported muscle symptoms rated using a visual analogue scale on the last week of each treatment period. Secondary outcomes included the participant\u2019s belief about the cause of their muscle symptoms, the site of muscle symptoms, how the muscle symptoms affected the participant, any other symptoms they experienced, adherence to medication, the participant\u2019s decision about statin treatment following the trial, and whether or not they found their own trial result helpful.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 151 out of 200 (75.5%) randomised participants provided one or more visual analogue scale measurements in a placebo period and one or more measurements in a statin period, and were included in the primary analysis. There was no evidence of a difference in muscle symptom scores between statin and placebo periods (mean difference statin minus placebo \u20130.11, 95% confidence interval \u20130.36 to 0.14; p<\/jats:italic>\u2009=\u20090.398). Withdrawals, adherence and missing data were similar during the statin periods and the placebo periods.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Among people who previously reported severe muscle symptoms while taking statins, this series of randomised N-of-1 trials found no overall effect of statins on muscle symptoms compared with the placebo. The slight difference in withdrawals due to muscle symptoms suggests that statins may contribute to symptoms in a small number of patients. The results are generalisable to patients who are considering discontinuing or have already discontinued statins because of muscle symptoms, and who are willing to re-challenge or participate in their own N-of-1 trial.<\/jats:p>\n <\/jats:sec>\n \n Future work<\/jats:title>\n We recommend that additional statins and doses are explored using N-of-1 trials. More broadly, N-of-1 trials present a useful tool for exploring transient symptoms with other medications.<\/jats:p>\n <\/jats:sec>\n \n Limitations<\/jats:title>\n This study used 20-mg doses of atorvastatin only. Furthermore, a dropout rate of 43% was observed, but this was accounted for in the power calculations.<\/jats:p>\n <\/jats:sec>\n \n Trial registration<\/jats:title>\n Current Controlled Trials ISRCTN30952488 and EudraCT 2016-000141-31.<\/jats:p>\n <\/jats:sec>\n \n Funding<\/jats:title>\n This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment<\/jats:italic>; Vol. 25, No. 16. See the NIHR Journals Library website for further project information.<\/jats:p>\n <\/jats:sec>","DOI":"10.3310\/hta25160","type":"journal-article","created":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T12:01:10Z","timestamp":1615550470000},"page":"1-62","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["The effect of statins on muscle symptoms in primary care: the StatinWISE series of 200 N-of-1 RCTs"],"prefix":"10.3310","volume":"25","clinical-trial-number":[{"clinical-trial-number":"isrctn30952488","registry":"10.18810\/isrctn","type":"results"},{"clinical-trial-number":"2016-000141-31","registry":"10.18810\/euctr","type":"results"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9425-644X","authenticated-orcid":true,"given":"Emily","family":"Herrett","sequence":"first","affiliation":[{"name":"Department of Non-communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6905-876X","authenticated-orcid":true,"given":"Elizabeth","family":"Williamson","sequence":"additional","affiliation":[{"name":"Department of Medical Statistics, London School of Hygiene & Tropical Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8100-8949","authenticated-orcid":true,"given":"Kieran","family":"Brack","sequence":"additional","affiliation":[{"name":"Liver Research, King\u2019s College Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9817-2390","authenticated-orcid":true,"given":"Alexander","family":"Perkins","sequence":"additional","affiliation":[{"name":"Clinical Trials Unit, London School of Hygiene & Tropical Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9702-1662","authenticated-orcid":true,"given":"Andrew","family":"Thayne","sequence":"additional","affiliation":[{"name":"Clinical Trials Unit, London School of Hygiene & Tropical Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6511-109X","authenticated-orcid":true,"given":"Haleema","family":"Shakur-Still","sequence":"additional","affiliation":[{"name":"Clinical Trials Unit, London School of Hygiene & Tropical Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1596-6054","authenticated-orcid":true,"given":"Ian","family":"Roberts","sequence":"additional","affiliation":[{"name":"Clinical Trials Unit, London School of Hygiene & Tropical Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7470-4823","authenticated-orcid":true,"given":"Danielle","family":"Prowse","sequence":"additional","affiliation":[{"name":"Clinical Trials Unit, London School of Hygiene & Tropical Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2530-9608","authenticated-orcid":true,"given":"Danielle","family":"Beaumont","sequence":"additional","affiliation":[{"name":"Clinical Trials Unit, London School of Hygiene & Tropical Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3817-6795","authenticated-orcid":true,"given":"Zahra","family":"Jamal","sequence":"additional","affiliation":[{"name":"Clinical Trials Unit, London School of Hygiene & Tropical Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5127-4728","authenticated-orcid":true,"given":"Ben","family":"Goldacre","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9363-742X","authenticated-orcid":true,"given":"Tjeerd","family":"van Staa","sequence":"additional","affiliation":[{"name":"Division of Informatics, Imaging and Data Sciences, University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5189-6669","authenticated-orcid":true,"given":"Thomas M","family":"MacDonald","sequence":"additional","affiliation":[{"name":"Medicines Monitoring Unit, School of Medicine, University of Dundee, Dundee, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8691-9226","authenticated-orcid":true,"given":"Jane","family":"Armitage","sequence":"additional","affiliation":[{"name":"Medical Research Council Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5127-4509","authenticated-orcid":true,"given":"Michael","family":"Moore","sequence":"additional","affiliation":[{"name":"School of Primary Care and Population Sciences, University of Southampton, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8860-4786","authenticated-orcid":true,"given":"Maurice","family":"Hoffman","sequence":"additional","affiliation":[{"name":"London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9168-6022","authenticated-orcid":true,"given":"Liam","family":"Smeeth","sequence":"additional","affiliation":[{"name":"Department of Non-communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2021,3]]},"reference":[{"key":"key20210311102816163_ref1-bib1","doi-asserted-by":"publisher","first-page":"N135","DOI":"10.1136\/bmj.n135","article-title":"Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials","volume":"372","author":"Herrett","year":"2021","journal-title":"BMJ"},{"key":"key20210311102816163_ref1-bib2","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","article-title":"Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials","volume":"385","author":"Fulcher","year":"2015","journal-title":"Lancet"},{"key":"key20210311102816163_ref1-bib3","first-page":"407","article-title":"Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials","volume":"393","author":"Cholesterol Treatment Trialists\u2019 Collaboration","year":"2016","journal-title":"Lancet"},{"key":"key20210311102816163_ref1-bib4","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"key":"key20210311102816163_ref1-bib5","doi-asserted-by":"publisher","first-page":"f6123","DOI":"10.1136\/bmj.f6123","article-title":"Should people at low risk of cardiovascular disease take a statin?","volume":"347","author":"Abramson","year":"2013","journal-title":"BMJ"},{"key":"key20210311102816163_ref1-bib6","doi-asserted-by":"publisher","first-page":"f6340","DOI":"10.1136\/bmj.f6340","article-title":"Saturated fat is not the major issue","volume":"347","author":"Malhotra","year":"2013","journal-title":"BMJ"},{"key":"key20210311102816163_ref1-bib7","doi-asserted-by":"publisher","first-page":"526","DOI":"10.7326\/0003-4819-158-7-201304020-00004","article-title":"Discontinuation of statins in routine care settings: a cohort study","volume":"158","author":"Zhang","year":"2013","journal-title":"Ann Intern Med"},{"key":"key20210311102816163_ref1-bib8","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1097\/JCN.0b013e3181ae7b2a","article-title":"Exploring patients\u2019 reasons for discontinuance of heart medications","volume":"24","author":"Garavalia","year":"2009","journal-title":"J Cardiovasc Nurs"},{"key":"key20210311102816163_ref1-bib9","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1093\/eurheartj\/ehv641","article-title":"Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study","volume":"37","author":"Nielsen","year":"2016","journal-title":"Eur Heart J"},{"key":"key20210311102816163_ref1-bib10","doi-asserted-by":"publisher","first-page":"591","DOI":"10.5694\/mja15.00103","article-title":"The crux of the matter: did the ABC\u2019s catalyst program change statin use in Australia?","volume":"202","author":"Schaffer","year":"2015","journal-title":"Med J Aust"},{"key":"key20210311102816163_ref1-bib11","doi-asserted-by":"publisher","first-page":"i3283","DOI":"10.1136\/bmj.i3283","article-title":"Impact of statin related media coverage on use of statins: interrupted time series analysis with UK primary care data","volume":"353","author":"Matthews","year":"2016","journal-title":"BMJ"},{"key":"key20210311102816163_ref1-bib12","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1001\/jama.287.5.622","article-title":"Nonspecific medication side effects and the nocebo phenomenon","volume":"287","author":"Barsky","year":"2002","journal-title":"JAMA"},{"key":"key20210311102816163_ref1-bib13","doi-asserted-by":"publisher","first-page":"i3305","DOI":"10.1136\/bmj.i3305","article-title":"Discontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database","volume":"353","author":"Vinogradova","year":"2016","journal-title":"BMJ"},{"key":"key20210311102816163_ref1-bib14","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/bcp.12339","article-title":"Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review","volume":"78","author":"De Vera","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"key20210311102816163_ref1-bib15","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","article-title":"Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial","volume":"9","author":"Moriarty","year":"2015","journal-title":"J Clin Lipidol"},{"key":"key20210311102816163_ref1-bib16","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1161\/CIRCULATIONAHA.106.624890","article-title":"Risks associated with statin therapy: a systematic overview of randomized clinical trials","volume":"114","author":"Kashani","year":"2006","journal-title":"Circulation"},{"key":"key20210311102816163_ref1-bib17","doi-asserted-by":"publisher","first-page":"e1001526","DOI":"10.1371\/journal.pmed.1001526","article-title":"Completeness of reporting of patient-relevant clinical trial outcomes: comparison of unpublished clinical study reports with publicly available data","volume":"10","author":"Wieseler","year":"2013","journal-title":"PLOS Med"},{"key":"key20210311102816163_ref1-bib18","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","article-title":"Rosuvastatin in older patients with systolic heart failure","volume":"357","author":"Kjekshus","year":"2007","journal-title":"N Engl J Med"},{"key":"key20210311102816163_ref1-bib19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","author":"Heart Protection Study Collaborative Group","year":"2002","journal-title":"Lancet"},{"key":"key20210311102816163_ref1-bib20","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"key20210311102816163_ref1-bib21","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel statement on assessment, aetiology and management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"key":"key20210311102816163_ref1-bib22","volume-title":"Statin Intolerance Tool","author":"American College of Cardiology"},{"key":"key20210311102816163_ref1-bib23","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S1567-5688(17)30024-7","article-title":"Practical aspects in the management of statin-associated muscle symptoms (SAMS)","volume":"26","author":"Laufs","year":"2017","journal-title":"Atheroscler Suppl"},{"key":"key20210311102816163_ref1-bib24","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1056\/NEJM198604033141406","article-title":"Determining optimal therapy \u2013 randomized trials in individual patients","volume":"314","author":"Guyatt","year":"1986","journal-title":"N Engl J Med"},{"key":"key20210311102816163_ref1-bib25","doi-asserted-by":"publisher","first-page":"e016604","DOI":"10.1136\/bmjopen-2017-016604","article-title":"Study protocol for statin web-based investigation of side effects (StatinWISE): a series of randomised controlled N-of-1 trials comparing atorvastatin and placebo in UK primary care","volume":"7","author":"Herrett","year":"2017","journal-title":"BMJ Open"},{"key":"key20210311102816163_ref1-bib26","unstructured":"National Institute for Health and Care Excellence (NICE). Cardiovascular Disease: Risk Assessment and Reduction, Including Lipid Modification. NICE Clinical Guideline 181. London: NICE; 2014."},{"key":"key20210311102816163_ref1-bib27","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1017\/s0033291700009934","article-title":"Clinical applications of visual analogue scales: a critical review","volume":"18","author":"McCormack","year":"1988","journal-title":"Psychol Med"},{"key":"key20210311102816163_ref1-bib28","doi-asserted-by":"publisher","first-page":"e28124","DOI":"10.1371\/journal.pone.0028124","article-title":"Statin-associated muscular and renal adverse events: data mining of the public version of the FDA adverse event reporting system","volume":"6","author":"Sakaeda","year":"2011","journal-title":"PLOS ONE"},{"key":"key20210311102816163_ref1-bib29","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/j.1553-2712.1996.tb03402.x","article-title":"The minimum clinically important difference in physician-assigned visual analog pain scores","volume":"3","author":"Todd","year":"1996","journal-title":"Acad Emerg Med"},{"key":"key20210311102816163_ref1-bib30","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1067\/mem.2001.118863","article-title":"Prospective validation of clinically important changes in pain severity measured on a visual analog scale","volume":"38","author":"Gallagher","year":"2001","journal-title":"Ann Emerg Med"},{"key":"key20210311102816163_ref1-bib31","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jacl.2012.03.003","article-title":"Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users","volume":"6","author":"Cohen","year":"2012","journal-title":"J Clin Lipidol"},{"key":"key20210311102816163_ref1-bib32","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/oxfordjournals.eurheartj.a060485","article-title":"Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study","volume":"15","author":"Keech","year":"1994","journal-title":"Eur Heart J"},{"key":"key20210311102816163_ref1-bib33","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1093\/bja\/aen103","article-title":"Assessment of pain","volume":"101","author":"Breivik","year":"2008","journal-title":"Br J Anaesth"},{"key":"key20210311102816163_ref1-bib34","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/S0197-2456(97)00008-1","article-title":"Clinical trials with multiple outcomes: a statistical perspective on their design, analysis, and interpretation","volume":"18","author":"Pocock","year":"1997","journal-title":"Controlled Clin Trials"},{"key":"key20210311102816163_ref1-bib35","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1056\/NEJMc2031173","article-title":"N-of-1 trial of a statin, placebo, or no treatment to assess side effects","volume":"383","author":"Wood","year":"2020","journal-title":"N Engl J Med"},{"key":"key20210311102816163_ref1-bib36","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ahj.2016.01.016","article-title":"Protocol for analyses of adverse event data from randomized controlled trials of statin therapy","volume":"176","author":"Cholesterol Treatment Trialists\u2019 Collaboration","year":"2016","journal-title":"Am Heart J"},{"key":"key20210311102816163_ref1-bib37","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/1741-7015-12-51","article-title":"Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis","volume":"12","author":"Macedo","year":"2014","journal-title":"BMC Med"},{"key":"key20210311102816163_ref1-bib38","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1016\/S0140-6736(17)31075-9","article-title":"Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase","volume":"389","author":"Gupta","year":"2017","journal-title":"Lancet"},{"key":"key20210311102816163_ref1-bib39","doi-asserted-by":"publisher","first-page":"221","DOI":"10.7326\/M16-0838","article-title":"Continued statin prescriptions after adverse reactions and patient outcomes: a cohort study","volume":"167","author":"Zhang","year":"2017","journal-title":"Ann Intern Med"},{"key":"key20210311102816163_ref1-bib40","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.ahj.2013.06.004","article-title":"Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience","volume":"166","author":"Mampuya","year":"2013","journal-title":"Am Heart J"},{"key":"key20210311102816163_ref1-bib41","doi-asserted-by":"publisher","first-page":"543","DOI":"10.7326\/M18-0808","article-title":"Statins and multiple noncardiovascular outcomes: umbrella review of meta-analyses of observational studies and randomized controlled trials","volume":"169","author":"He","year":"2018","journal-title":"Ann Intern Med"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2036169","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta25160\/hta25160.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2036169","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T15:34:15Z","timestamp":1692113655000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/hta25160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":41,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2021,3]]}},"alternative-id":["10.3310\/hta25160"],"URL":"https:\/\/doi.org\/10.3310\/hta25160","relation":{},"ISSN":["1366-5278","2046-4924"],"issn-type":[{"value":"1366-5278","type":"print"},{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"},{"value":"4-2016","name":"contractual_start_date","label":"Contractual start date","group":{"name":"article_history","label":"Article History"}},{"value":"10-2019","name":"editorial_review_begun","label":"Editorial review begun","group":{"name":"article_history","label":"Article History"}},{"value":"3-2020","name":"accepted_for_publication","label":"Accepted for publication","group":{"name":"article_history","label":"Article History"}}]}}